Original article
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis
La prevalencia de cáncer en pacientes con esclerosis múltiple (EM) que recibieron rituximab: una revisión sistemática y meta-análisis
O. Mirmosayyeba, V. Shaygannejada, N. Ebrahimia, H. Ghoshounia, M. Ghajarzadehb,
Corresponding author
a Department of Neurology, School of Medicine, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
b Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Read
667
Timeswas read the article
147
Total PDF
520
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 16 | 0 | 16 |
| 2024 June | 40 | 15 | 55 |
| 2024 May | 19 | 8 | 27 |
| 2024 April | 47 | 3 | 50 |
| 2024 March | 50 | 8 | 58 |
| 2024 February | 63 | 8 | 71 |
| 2024 January | 32 | 4 | 36 |
| 2023 December | 33 | 8 | 41 |
| 2023 November | 53 | 18 | 71 |
| 2023 October | 51 | 14 | 65 |
| 2023 September | 15 | 4 | 19 |
| 2023 August | 17 | 3 | 20 |
| 2023 July | 6 | 11 | 17 |
| 2023 June | 14 | 2 | 16 |
| 2023 May | 40 | 4 | 44 |
| 2023 April | 24 | 2 | 26 |
| 2023 March | 0 | 3 | 3 |
| 2023 February | 0 | 9 | 9 |
| 2023 January | 0 | 5 | 5 |
| 2022 December | 0 | 4 | 4 |
| 2022 November | 0 | 12 | 12 |
| 2022 October | 0 | 2 | 2 |
Show all
